Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?

23 Jul 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

FDA's Budget Flat In House Bill, But Path For 'Cures' Funding Cleared

29 Jun 2017

White House Slams Generic Exclusivity Provisions In User Fee Bill

14 Jul 2017

FDA Expanding Opioid REMS To Immediate Release Formulations

11 Jul 2017

Opioid Prescriber Training: US FDA Still Debating Mandate; CMS Policies Having Impact Now

25 May 2017

Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says

24 May 2017

Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails

28 Mar 2017

Restrictive REMS Is Least Favored Path For Opioid Prescriber Education

09 May 2016

Drug Abuse And US Presidential Politics: Surprising Bipartisan Agreement

02 Nov 2016

Additional Topics

United States Risk Management Legislation FDA Regulation Drug Safety Neurology BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.